Benralizumab treatment in patients with severe asthma: A comparative analysis of T-cell gene expression profiles and identification of response-associated genes

Benralizumab, an antibody that targets the interleukin-5 (IL-5) receptor, suppresses IL-5 activity, which plays a critical role in eosinophil development. Clinical studies have shown its efficacy in reducing eosinophil counts in both the blood and sputum, which has been shown to be beneficial for patients with severe asthma. In this study, we analyzed the gene expression patterns of T cells in 17 patients with severe asthma treated with benralizumab. Comparisons were made between baseline (week 0) and post-treatment (week 24) samples. In addition, this study aimed to identify specific genes associated with the treatment response. Overall design: A comparative study examined T-cell gene expression patterns in patients with severe asthma, evaluating changes from baseline (week 0) to 24 weeks after the initiation of benralizumab therapy.